Nasal spray emitting a shield of light, symbolizing cervical cancer prevention.

Can a Nasal Vaccine Prevent Cervical Cancer? The Surprising Role of Flagellin

Rhea Morgan in Health & Wellness October 2026 • 4 min read.

"New research explores how a flagellin-adjuvanted peptide vaccine, delivered through the nose, could enhance the body's immune response and prevent tumor development in HPV-related cancers."

Cervical cancer remains a significant threat to women's health worldwide, with human papillomavirus (HPV) identified as a primary cause. Current strategies focus on preventative vaccines that stimulate the production of neutralizing antibodies. However, mucosal vaccines, which target the immune system at the point of entry for many pathogens, often struggle to elicit a strong enough response.

Researchers are exploring new approaches to enhance the effectiveness of mucosal vaccines. One promising avenue involves the use of adjuvants—substances that boost the immune response. Flagellin, a protein derived from bacteria, has shown potential as a powerful adjuvant due to its ability to activate Toll-like receptor 5 (TLR5), a key component of the immune system.

A recent study investigated whether flagellin could enhance the efficacy of a peptide-based HPV vaccine delivered through the nose. The results offer exciting insights into the potential of this approach for preventing cervical cancer. This article breaks down the study's findings, explaining how a flagellin-adjuvanted vaccine can stimulate a robust immune response and protect against tumor development in a mouse model.

How Does a Flagellin-Adjuvanted Nasal Vaccine Work?

Nasal spray emitting a shield of light, symbolizing cervical cancer prevention.

The study, published in Clinical and Experimental Vaccine Research, details how researchers administered a vaccine containing HPV-16 E6 and E7 peptides (short protein fragments associated with cervical cancer) along with flagellin to mice through the nose. The mice received two doses of the vaccine, with researchers then analyzing their immune responses and monitoring tumor growth after implantation of TC-1 cells (cells bearing E6/E7 antigens).

The researchers observed a significant enhancement of the immune response in mice that received the flagellin-adjuvanted vaccine. Specifically, the vaccine:

Significantly increased cytotoxic T lymphocyte (CTL) activity, meaning the immune system was better equipped to kill cancer cells.
Enhanced the production of interferon-γ (IFN-γ), a signaling molecule that plays a crucial role in activating the immune system and fighting off infections.
Provided excellent protection against TC-1 tumor challenge, resulting in high survival rates in the vaccinated animals.

AI Search Multiple angles on this topic

Latest Research

Flagellin and Mucosal Immune Responses

A study of flagellin as a vaginal adjuvant reported that intranasal immunization with flagellin and E6/E7 peptides induced E6/E7-specific interferon-gamma production in draining cervical lymph nodes of naive mice. The researchers later measured responses in draining genital lymph nodes to better reflect local antitumor activity in genital cancer. A review likewise reports that intranasal flagellin-adjuvanted peptides enhanced specific cytotoxic T-lymphocyte responses in prophylactic cancer-vaccine models. Separately, WHO reports that, as of 2025, eight HPV vaccines were licensed, with five receiving WHO prequalification and being available globally.

Counterpoints

Promising Mice, Established Prevention

The flagellin-adjuvanted peptide vaccine evidence described here comes from a mouse TC-1 cervical cancer model, in which E6- and E7-specific cytotoxic T-lymphocyte responses were evaluated because they are important for tumor eradication. This preclinical result does not establish that a nasal flagellin vaccine prevents cervical cancer in humans. In contrast, CDC reports that HPV vaccination is already preventing cancer-causing infections, anogenital warts, and cervical precancers, with early evidence of effectiveness against cervical cancer in some countries. CDC also states that HPV vaccination does not cause fertility problems, while treatment for HPV-related cancer can sometimes limit the ability to have children.

Comparison

Nasal Research Versus HPV Vaccination

Persistent infection with high-risk HPV is identified as the key factor in cervical cancer development, and HPV vaccines aim to prevent cancer by preventing that infection. Another review notes that virtually all cervical cancer cases are related to HPV and that more than 200 million HPV vaccine doses have been administered worldwide. Comparative vaccine research has also examined cross-protection against oncogenic HPV, including the HPV-16/18 AS04-adjuvanted cervical cancer vaccine. These sources describe established HPV-vaccine prevention strategies, whereas the flagellin approach is presented as a distinct mucosal, therapeutic or experimental vaccine concept.

These findings suggest that flagellin acts as a potent mucosal adjuvant, boosting the immune response to the E6/E7 peptides and leading to effective tumor control. The nasal route of administration is particularly appealing because it targets the mucosal immune system, which is the first line of defense against many pathogens, including HPV.

The Future of HPV Vaccines: A Nasal Spray?

The results of this study offer a promising glimpse into the future of HPV vaccines. The use of flagellin as a mucosal adjuvant, combined with nasal administration, could lead to more effective and accessible vaccines for preventing cervical cancer. This is particularly important in developing countries, where cervical cancer rates are high and access to healthcare is limited.

AI Search Multiple angles on this topic

Expert View

Evidence Favors HPV Vaccination

A May 8, 2026 review of hundreds of HPV vaccine studies reinforced longstanding evidence that HPV vaccines are highly safe and effective at preventing persistent HPV infection, precancerous cervical changes, and cervical cancer. The analysis found no credible link between HPV vaccination and serious long-term health risks. This evidence supports HPV vaccination as the established prevention benchmark when considering experimental approaches such as a flagellin-based nasal vaccine.

Real-World Impact

Access, Timing, and Real-World Protection

Long-term, brand-specific real-world safety data remain limited even though clinical trials have established favorable safety profiles for HPV vaccines. A population-level study found high HPV vaccine effectiveness against cervical cancer among girls vaccinated before age 20, while finding no immediate effect among women vaccinated at ages 20 to 30 and emphasizing the importance of early vaccination. Research from the United States and Sweden reported that differences in cervical cancer risk mirrored HPV vaccine coverage. The findings suggest that policy choices and access to immunization are already shaping women’s real-world risk of developing cervical cancer.

While these findings are encouraging, it's important to note that this study was conducted in mice. Further research is needed to confirm these results in humans and to evaluate the safety and efficacy of flagellin-adjuvanted nasal HPV vaccines in clinical trials.

If successful, this innovative approach could revolutionize cervical cancer prevention, offering a needle-free, easily administered vaccine that harnesses the power of the mucosal immune system. The potential impact on women's health worldwide is significant, paving the way for a future where cervical cancer is a preventable disease.

What a mouse tumor-challenge study can establish

Animal study (level 5 of 8)

Because this was an animal study, it can show how the vaccine performed in the tested mice and model, but it cannot establish whether it prevents cervical cancer in people.^{[1] [2]}

The study measured tumor growth and survival after mice were challenged with TC-1 cells bearing E6/E7 antigens, so its results concern this experimental challenge rather than naturally acquired HPV infection.^{[1] [2]}

Tumor measurements against the control

1,048±191; 172±112 mm³Three weeks after challenge, the PBS control group had a mean tumor volume of 1,048±191 mm3; the FlaB-plus-peptide group measured 172±112 mm3 and was reported as significantly smaller than the peptide-only group.^[1]

What the immune and tumor results add up to

The peptide-plus-FlaB combination performed better than peptide alone on both a tumor-cell killing measure and the reported tumor-size comparison. That pattern is consistent with FlaB strengthening the response to the peptides in this mouse model, but does not show that the nasal approach prevents human cancer.^{[1] [2]}

The immune-cell assay found more E6/E7-specific IFN-γ-producing cells in the combination group than in the peptide-only group in both sampled tissues. This adds an immune-response measure alongside the tumor outcomes, rather than demonstrating protection against HPV infection.^{[1] [2]}

Intranasal FlaB and E6/E7 peptides tested in mice

Study design	Animal study^[2]
Comparison	PBS control, FlaB only, and peptide only groups^[2]
Main outcome	Tumor growth and survival after TC-1 tumor challenge^[2]
Times cited	21^[2]

A later study distinguished this nasal experiment from its own vaginal immunization work: it said the earlier nasal study measured E6/E7-specific IFN-γ responses in cervical lymph nodes, while the later work sampled genital lymph nodes to examine local responses more closely tied to genital tumor activity.^[3]

What a follow-up would need to clarify

Would the combination retain its tumor-control effect when the antigen or experimental setup changes, given the paper's caution about inconsistent FlaB findings?^[1]
Would a nasal formulation produce immune activity in genital tissues comparable to the local responses examined in later vaginal-vaccine work?^[3]
Can the measured immune response translate into protection in people, rather than only in mice challenged with implanted tumor cells?^{[1] [2]}

Terms used in the study

ELISPOT: An assay used in the study to determine the number of peptide-specific IFN-γ-producing cells.^[1]

Sources

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.7774/cevr.2013.2.2.128, Alternate LINK

Title: Intranasal Immunization With A Flagellin-Adjuvanted Peptide Anticancer Vaccine Prevents Tumor Development By Enhancing Specific Cytotoxic T Lymphocyte Response In A Mouse Model

Subject: Infectious Diseases

Journal: Clinical and Experimental Vaccine Research

Publisher: Korean Vaccine Society

Authors: Chung Truong Nguyen, Seol Hee Hong, Thuan Trong Ung, Vivek Verma, Soo Young Kim, Joon Haeng Rhee, Shee Eun Lee

Published: 2013-01-01

Everything You Need To Know

How does a flagellin-adjuvanted nasal vaccine work?

The HPV vaccine uses a flagellin-adjuvanted peptide, given through the nose. This approach targets the mucosal immune system, which is the body's first line of defense. The vaccine contains HPV-16 E6 and E7 peptides and flagellin. This combination significantly boosts the immune response, particularly the cytotoxic T lymphocyte (CTL) activity, enhancing the body's ability to kill cancer cells.

What is flagellin and why is it used in this vaccine?

Flagellin is a protein derived from bacteria. It is used as an adjuvant in the vaccine because it activates Toll-like receptor 5 (TLR5), a crucial part of the immune system. By activating TLR5, flagellin boosts the immune response to the HPV peptides, resulting in enhanced protection against tumor development. Without the flagellin, the immune response to the vaccine would not be as strong, and its effectiveness would be diminished.

What are cytotoxic T lymphocytes (CTLs) and what is their role in this vaccine's effectiveness?

Cytotoxic T lymphocytes (CTLs), also known as killer T cells, are a type of immune cell that can recognize and destroy cells infected with viruses or cancer cells. The flagellin-adjuvanted vaccine significantly increases CTL activity. The CTLs become more effective at identifying and eliminating cells infected with HPV or that have become cancerous. This is vital because it directly addresses the cancerous cells, preventing tumor growth and increasing survival rates.

Why is the nasal route of administration important for this HPV vaccine?

The nasal route is particularly appealing because it targets the mucosal immune system. This is the body's initial defense against pathogens like HPV. Mucosal vaccines aim to stimulate an immune response at the point of entry for pathogens. By administering the vaccine nasally, the immune system in the nasal passages is directly activated, leading to a more effective and targeted immune response against HPV. This approach could potentially lead to more accessible and effective vaccines.

What is the significance of interferon-γ (IFN-γ) in the context of this vaccine?

Interferon-γ (IFN-γ) is a signaling molecule that plays a vital role in activating the immune system and fighting infections. The flagellin-adjuvanted vaccine enhances IFN-γ production. High levels of IFN-γ signal that the immune system is effectively fighting the HPV infection or cancer. This heightened IFN-γ production is critical for controlling tumor growth and improving survival rates in vaccinated animals. It is an indicator of the immune system's robust response to the vaccine.